Eden Research (LON:EDEN) Shares Down 13.2% – Should You Sell?

by · The Cerbat Gem

Eden Research plc (LON:EDEN – Get Free Report)’s stock price traded down 13.2% on Monday . The company traded as low as GBX 2.26 ($0.03) and last traded at GBX 2.37 ($0.03). 1,775,147 shares changed hands during mid-day trading, an increase of 133% from the average session volume of 762,776 shares. The stock had previously closed at GBX 2.73 ($0.04).

Eden Research Trading Up 3.5 %

The firm’s 50-day simple moving average is GBX 3.36 and its 200 day simple moving average is GBX 3.71. The stock has a market capitalization of £14.35 million, a P/E ratio of -9.42 and a beta of 0.92. The company has a quick ratio of 2.42, a current ratio of 3.80 and a debt-to-equity ratio of 1.26.

Insider Buying and Selling at Eden Research

In other Eden Research news, insider Sean M. Smith acquired 426,986 shares of the business’s stock in a transaction on Tuesday, April 1st. The stock was purchased at an average price of GBX 234 ($3.03) per share, for a total transaction of £999,147.24 ($1,291,722.35). Also, insider Lykele van der Broek purchased 256,000 shares of the firm’s stock in a transaction dated Thursday, February 6th. The shares were bought at an average cost of GBX 4 ($0.05) per share, for a total transaction of £10,240 ($13,238.53). Insiders have purchased a total of 1,391,473 shares of company stock worth $103,604,725 over the last three months. Corporate insiders own 14.02% of the company’s stock.

Eden Research Company Profile

(Get Free Report)

Eden Research is the only UK-listed company focused on biopesticides for sustainable agriculture. It develops and supplies innovative biopesticide products and natural microencapsulation technologies to the global crop protection, animal health and consumer products industries.

Eden’s products are formulated with terpene active ingredients, based on natural plant defence metabolites.

Featured Articles